綠葉製藥(02186.HK)獲執行董事兼執行主席劉殿波增持共200萬股
格隆匯1月12日丨綠葉製藥(02186.HK)公吿,公司董事會獲公司執行董事兼執行主席劉殿波先生通知,彼於2024年1月12日透過其受控法團綠葉製藥投資有限公司於市場內購入合共公司200萬股普通股,平均購入價為每股股份約3.3112港元。
進行購買後及於本公吿日期,劉先生於12.6億股股份中擁有權益,佔公司已發行股本總額約33.47%。
如劉先生所吿知,彼對公司的增長、發展及未來前景充滿信心,並可能於適當時在適用法律及法規的規限下進一步增加彼於股份的權益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.